Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dyne Therapeutics, Inc. announced the grant of inducement equity awards to 11 newly hired employees, as per Nasdaq Listing Rule 5635(c)(4). These awards include non-statutory stock options for 161,300 shares and restricted stock units for 51,200 shares, both vesting over four years. The grants are intended to attract and retain talent for the clinical-stage company focused on genetically driven neuromuscular diseases.
Handelsbanken Fonder AB Acquires Shares of 53,200 Dyne Therapeutics, Inc. $DYN
Handelsbanken Fonder AB recently acquired 53,200 shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) valued at approximately $1.18 million, contributing to institutional investors owning 96.68% of the company. Analysts maintain a "Moderate Buy" rating with a consensus target price of $34.42, despite the company reporting a wider-than-expected quarterly loss and significant insider selling.
Flputnam Investment Management Co. Makes New Investment in Dyne Therapeutics, Inc. $DYN
Flputnam Investment Management Co. has acquired a new stake of 52,975 shares in Dyne Therapeutics, Inc., valued at approximately $1,177,000, during the second quarter. This move is part of a broader trend of institutional investment in Dyne Therapeutics, with several other large investors also increasing their positions. The company has received a "Moderate Buy" rating from analysts with a consensus target price of $34.42, despite recent insider selling by its CFO and a director.
Aegis Wealth Management LLC Invests $3.33 Million in Dyne Therapeutics, Inc. $DYN
Aegis Wealth Management LLC has acquired a new stake of 150,030 shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) valued at approximately $3.33 million, making it their 9th largest holding. Other institutional investors have also adjusted their positions in Dyne Therapeutics, with the company's stock trading up 1.8% and having a market capitalization of $4.88 billion. Analyst ratings for Dyne Therapeutics currently show a "Moderate Buy" consensus with an average price target of $34.42, despite recent insider sales and a reported earnings per share miss.
Dyne therapeutics director Jason Rhodes sells $65.2m of common stock
Dyne Therapeutics director Jason P. Rhodes sold approximately $65.2 million worth of common stock through various Atlas Venture funds on August 13 and 14, 2026. The sales were executed under a Rule 10b5-1 trading plan as the DYN stock traded near its 52-week high. These transactions occurred amidst significant company news, including the FDA's Priority Review for its Duchenne muscular dystrophy treatment and a $375 million public stock offering.
Dyne Therapeutics (NASDAQ: DYN) CCO sells shares to cover taxes
Dyne Therapeutics' Chief Commercial Officer, Johanna Friedl-Naderer, reported an automatic sale of 226 shares of common stock at a weighted average price of $26.28 per share on August 13, 2026. This transaction was conducted to satisfy tax withholding obligations related to the vesting of restricted stock units under a pre-arranged Rule 10b5-1 binding contract, rather than being a discretionary trade. Following the sale, Friedl-Naderer directly holds 153,982 shares, which includes 119,928 unvested restricted stock units.
Dyne therapeutics director Jason Rhodes sells $65.2m of common stock
Jason P. Rhodes, a Director at Dyne Therapeutics, Inc., recently sold approximately $65.2 million worth of common stock over two days, August 13 and 14, 2026, under a pre-arranged trading plan. The shares were sold at prices ranging from $25.00 to $26.20, with the stock trading near its 52-week high and considered overvalued by InvestingPro. This comes amidst other company news, including FDA acceptance of a Biologics License Application for Duchenne muscular dystrophy and a recent $375 million public stock offering.
Dyne therapeutics CFO Erick Lucera sells $47,225 in stock
Dyne Therapeutics CFO Erick Lucera sold $47,225 worth of company stock to cover tax withholding obligations related to restricted stock unit vesting. The sale of 1,797 shares occurred when Dyne's stock was near its 52-week high, with the company also announcing FDA Priority Review for a Duchenne muscular dystrophy treatment and recent stock offerings. Analysts have issued positive ratings for Dyne Therapeutics, which plans to release topline results from a clinical trial in Q1 2027.
Insider Selling: Dyne Therapeutics (NASDAQ:DYN) Director Sells $54,012,900.00 in Stock
Dyne Therapeutics director Jason Rhodes sold over 2.16 million shares of DYN stock for approximately $54 million, reducing his direct ownership by 83.43% through a pre-arranged Rule 10b5-1 plan. Despite the significant insider selling and a recent EPS miss, Dyne Therapeutics shares rose, trading near their 52-week high. Analysts maintain a "Moderate Buy" consensus with a target price of $34.42, and institutional investors hold a substantial portion of the company's stock.
Jason Rhodes Sells 426,412 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock
Jason Rhodes, a director at Dyne Therapeutics (NASDAQ:DYN), sold 426,412 shares of the company's stock for approximately $11.17 million. This transaction, executed under a Rule 10b5-1 trading plan, reduced his direct ownership by 36.2%. Despite missing analyst earnings expectations, Dyne Therapeutics shares rose, trading near their 52-week high, and the company maintains a "Moderate Buy" consensus rating from analysts.
Dyne therapeutics CFO Erick Lucera sells $47,225 in stock
Dyne Therapeutics CFO Erick Lucera sold $47,225 worth of company stock, an automatic transaction to cover tax obligations from vested restricted stock units. This sale occurred while Dyne shares were near their 52-week high, following a significant 108% return over the past year. The company recently saw its Biologics License Application accepted by the FDA for zeleciment rostudirsen with Priority Review and also priced a $375 million public stock offering.
Dyne Therapeutics (DYN) CEO's tax-driven sale to cover RSU taxes
Dyne Therapeutics (DYN) CEO & President John Cox reported an automatic sale of 4,986 shares of Common Stock on August 13, 2026, at a weighted average price of $26.28 per share. This sale was conducted to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 12, 2026, and was not a discretionary trade, consistent with a Rule 10b5-1 binding contract. Following the transaction, Cox directly holds 363,165 shares, including 248,314 unvested RSUs, and indirectly holds 18,000 shares in each of four trusts for the benefit of a child.
Dyne Therapeutics (DYN) CFO sells shares in tax withholding trade
Dyne Therapeutics CFO Erick Lucera sold 1,797 shares of common stock on August 13, 2026, at a weighted average price of $26.28 per share. This sale was an automatic disposition to cover tax withholding obligations upon the vesting of restricted stock units, as part of a pre-existing Rule 10b5-1 binding contract, and was not a discretionary trade. Following the transaction, Lucera directly holds 119,766 shares, including 106,451 unvested RSUs.
Wainwright reiterates Dyne Therapeutics stock rating on trial outlook
H.C. Wainwright has reiterated a Buy rating and a $50.00 price target for Dyne Therapeutics (NASDAQ:DYN), citing the upcoming HARBOR trial data readout as a significant catalyst for DM1 treatment. The firm anticipates the HARBOR trial will meet its primary endpoint, drawing comparisons to positive results from Avidity's MARINA-OLE study. Dyne Therapeutics is also expected to release topline results from its ACHIEVE REC trial in Q1 2027, with recent activities including a $300 million equity offering and FDA Priority Review for its Duchenne muscular dystrophy treatment, z-rostudirsen.
Bank of America Corp DE Has $26.17 Million Holdings in Dyne Therapeutics, Inc. $DYN
Bank of America Corp DE significantly increased its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 63.5% in the first quarter, now holding 1.44 million shares valued at $26.17 million. Institutional investors and hedge funds collectively own 96.68% of DYN. While a director purchased shares, the CFO sold some, resulting in insiders buying $156,800 and selling $34.26 million worth of stock during the quarter. Despite missing quarterly EPS estimates, analysts maintain a "Moderate Buy" consensus with an average price target of $34.42.
Dyne Therapeutics, Inc. SEC Filing (Aug 14, 2026)
This article reports on a Form 144 SEC filing by Dyne Therapeutics, Inc. (DYN) on August 14, 2026. The filing indicates a proposed sale of 478,377 shares of common stock with an aggregate market value of $12,418,666.92, acquired via private placement in December 2022. The filing also notes that no securities were sold in the past three months by the person filing.
Dyne Therapeutics (DYN) gains 7.3% institutional holder Janus Henderson
Janus Henderson Group Ltd. filed an amended beneficial ownership report (SCHEDULE 13G/A) for Dyne Therapeutics Inc. (DYN), indicating that its affiliated asset managers beneficially own 11,997,738 shares, representing 7.3% of the class as of June 30, 2026. These shares are held in client Managed Portfolios, with asset managers exercising shared voting and dispositive power. Janus Henderson disclaims economic ownership, with dividends and sale proceeds going to the Managed Portfolios, none of which individually holds more than 5% of Dyne Therapeutics' common stock.
DYN (DYN) insider notice details planned share sale and prior trades
A recent SEC Form 144 filing indicates a planned sale of 1,797 common shares of Dyne Therapeutics (DYN) valued at $47,226.00, scheduled for August 13, 2026, on Nasdaq. These shares are part of equity compensation, including 4,062 restricted stock units from August 12, 2026. The filing also revealed a prior sale by Erick Lucera on June 25, 2026, of 2,362 shares for $48,103.00.
Dyne Therapeutics, Inc. SEC Filing (Aug 13, 2026)
Dyne Therapeutics, Inc. (DYN) filed a Form 144 SEC document on August 13, 2026, indicating a proposed sale of securities. The filing details information about the issuer, the filer, and the securities to be sold, including 94,415 shares of common stock acquired via private placement in 2022 with an aggregate market value of $2,470,840.55. The document was accepted by the SEC on the same date.
The Bull Case For Dyne Therapeutics (DYN) Could Change Following FDA Clearance Of DYNE-302 Trial
Dyne Therapeutics (DYN) received FDA clearance for a Phase 1 trial of DYNE-302, a treatment for facioscapulohumeral muscular dystrophy, adding to its clinical pipeline. While the company reported a wider net loss, this development, alongside other clinical assets, is seen as a key catalyst for investors. The article notes that despite potential undervaluation, the expanding trial footprint and accelerating losses lead to diverse opinions on the stock's risk and timing.
Dyne Therapeutics stock hits 52-week high at 27.19 USD
Dyne Therapeutics (DYN) has reached a 52-week high of $27.19, reflecting a nearly 130% total return over the past year and strong investor confidence. Despite this, InvestingPro analysis suggests the stock might be overvalued relative to its Fair Value. The company has also announced stock offerings to raise capital and received Priority Review from the FDA for its Duchenne muscular dystrophy treatment, zeleciment rostudirsen.
Dyne Therapeutics stock hits 52-week high at 27.19 USD By Investing.com
Dyne Therapeutics (DYN) stock reached a 52-week high of $27.19, reflecting a 1-year total return of nearly 130% and strong investor confidence. Despite this, InvestingPro analysis suggests the stock might be overvalued. The company recently priced two significant public stock offerings and received Priority Review for its Duchenne muscular dystrophy treatment, zeleciment rostudirsen, from the FDA, with analysts initiating "overweight" and "buy" ratings.
Biotech Stocks At 52-Week Highs - ALMR +30% On Q2 Reports, DYN, CGEM, DXCM, CAH
Several biotech stocks reached 52-week highs on August 11, 2026, driven by positive quarterly reports and key developments. Alamar Biosciences (ALMR) surged over 30% after reporting significant revenue growth and expanding partnerships for Alzheimer's research. Dyne Therapeutics (DYN) saw gains with its lead drug candidates progressing in clinical trials and FDA applications.
The Bull Case For Dyne Therapeutics (DYN) Could Change Following FDA Clearance Of DYNE-302 Trial
Dyne Therapeutics (DYN) received FDA clearance for a Phase 1 trial of DYNE-302, its third clinical program, targeting facioscapulohumeral muscular dystrophy (FSHD). This clearance, despite a wider net loss of US$178.56 million in Q2 2026, strengthens Dyne's investment narrative by adding another clinical asset to its pipeline alongside two other programs already in Phase 3. However, the increased R&D intensity and execution risk mean future trial outcomes and financing terms will be crucial for the company's valuation.
The Bull Case For Dyne Therapeutics (DYN) Could Change Following FDA Clearance Of DYNE-302 Trial
Dyne Therapeutics (DYN) reported a wider Q2 net loss of US$178.56 million but received FDA clearance for a Phase 1 trial of DYNE-302 for facioscapulohumeral muscular dystrophy (FSHD). This marks Dyne's third clinical program, leveraging its FORCE platform, and introduces a new catalyst for investors alongside existing trials. While the IND clearance is positive, it also increases R&D intensity and execution risk, making trial outcomes and financing critical for future stock performance.
The Bull Case For Dyne Therapeutics (DYN) Could Change Following FDA Clearance Of DYNE-302 Trial
Dyne Therapeutics (DYN) recently received FDA clearance to begin a Phase 1 trial for DYNE-302, targeting facioscapulohumeral muscular dystrophy, marking its third clinical program. This development, while positive, also highlights increased R&D intensity and execution risks, alongside the company's accelerating net losses. Investors are keenly watching the progress of DYNE-302, along with z-rostudirsen and z-basivarsen, as these programs are crucial for the company's investment narrative and future financing.
Dyne Therapeutics (DYN) Gets FDA Clearance With Valuation Questions Back In Focus
Dyne Therapeutics (DYN) received FDA clearance to begin a Phase 1 trial for DYNE-302, a treatment for facioscapulohumeral muscular dystrophy, leading to significant investor interest and a 135.22% one-year return. Despite recent momentum and a share price of $26.25, a Discounted Cash Flow model suggests a fair value of $38.83, indicating the stock is undervalued. However, the company faces risks, including a net loss of $519.41 million and clinical uncertainty due to its early stage and lack of revenue, contrasted by a high P/B ratio compared to the broader biotech industry.
Dyne Therapeutics (DYN) Gets FDA Clearance With Valuation Questions Back In Focus
Dyne Therapeutics (DYN) has gained FDA clearance to begin a Phase 1 trial for DYNE-302, a treatment for facioscapulohumeral muscular dystrophy, leading to increased investor attention and a 135.22% one-year shareholder return. Despite its current net loss and lack of revenue, a Discounted Cash Flow model suggests the stock is undervalued at $26.25 with a fair value of $38.83, while its P/B ratio indicates potential valuation risks. The article encourages investors to weigh these mixed signals and consider the company's risks and potential rewards.
Dimensional Fund Advisors LP Has $17.24 Million Holdings in Dyne Therapeutics, Inc. $DYN
Dimensional Fund Advisors LP significantly increased its stake in Dyne Therapeutics, Inc. by 870.3% in the first quarter, now holding shares valued at $17.24 million. Despite this, insiders have been net sellers, offloading over 1.5 million shares worth $34.39 million. Analysts maintain a "Moderate Buy" rating for DYN, though the company recently missed its quarterly EPS estimate.
Dyne Therapeutics stock hits 52-week high at 26.8 USD
Dyne Therapeutics (DYN) stock recently hit a 52-week high of $26.8 USD, reflecting a 124.07% increase over the past year. Despite an InvestingPro analysis suggesting it might be overvalued, the company has seen positive developments, including the FDA acceptance of its Biologics License Application for zeleciment rostudirsen and successful stock offerings. Analysts like Cantor Fitzgerald and TD Cowen have initiated coverage with positive ratings, further bolstering investor confidence.
FMR LLC (DYN) discloses 6.8% Dyne Therapeutics stake in amended ownership filing
FMR LLC has filed an amended beneficial ownership report for Dyne Therapeutics Inc. (DYN), disclosing a 6.8% stake in the company, representing 11,206,999.89 shares of common stock as of June 30, 2026. FMR LLC holds sole voting power over 11,206,231.00 shares and sole dispositive power over all 11,206,999.89 shares. Abigail P. Johnson also has sole dispositive power over the same number of shares, with other persons having rights to dividends or sale proceeds, though none exceeding five percent ownership.
Dyne Therapeutics stock hits 52-week high at 26.8 USD By Investing.com
Dyne Therapeutics Inc. stock reached a 52-week high of $26.80, marking a 124.07% increase over the past year. This surge is attributed to strong investor confidence, positive market sentiment, and recent developments such as the FDA's Priority Review for zeleciment rostudirsen for Duchenne muscular dystrophy. Analyst coverage from Cantor Fitzgerald and TD Cowen also reflects positive outlooks for the company.
How FDA Greenlight For DYNE-302 And Equity Raise At Dyne Therapeutics (DYN) Has Changed Its Investment Story
Dyne Therapeutics received FDA clearance to begin a Phase 1 trial for DYNE-302 in facioscapulohumeral muscular dystrophy, expanding its FORCE platform into a third clinical program. Despite a significant Q2 net loss of US$178.56 million, the company also raised US$375.15 million in an equity offering to extend its financial runway. These developments broaden Dyne's investment narrative beyond DMD but also increase R&D spending and shareholder dilution.
How FDA Greenlight For DYNE-302 And Equity Raise At Dyne Therapeutics (DYN) Has Changed Its Investment Story
Dyne Therapeutics has secured FDA clearance to initiate a Phase 1 trial for DYNE-302, targeting facioscapulohumeral muscular dystrophy, expanding its FORCE platform beyond DMD. This development comes after the company reported a significant net loss of US$178.56 million in Q2 and completed a US$375.15 million equity offering. The article explores how these events influence Dyne's investment narrative, balancing the potential for new therapies with increased R&D costs and shareholder dilution.
Dyne Therapeutics (DYN) Could Be 38% Undervalued As FDA Milestones Lift Pipeline Hopes
Dyne Therapeutics (DYN) appears to be 38% undervalued according to Simply Wall St's discounted cash flow (DCF) model, with an estimated fair value of $40.88 against a current share price of $25.18. This valuation comes after recent FDA milestones, including clearance for a Phase 1 trial for DYNE-302 and Priority Review for Duchenne candidate DYNE-251, contributing to significant share price momentum. However, as a pre-revenue biotech company reporting losses, future performance remains sensitive to clinical program outcomes and the stock also trades at a higher P/B ratio compared to the industry average.
DYNE THERAPEUTICS, INC : RBC RAISES TARGET PRICE TO $35 FROM $30
RBC Capital Markets has increased its target price for DYNE Therapeutics, Inc. (DYNE) shares to $35 from $30. This adjustment by the investment bank indicates a more optimistic outlook on the company's future stock performance.
Dyne Therapeutics Market Sentiment
This article analyzes the market sentiment for Dyne Therapeutics (DYN) by examining analyst consensus, short interest, options flow, and insider activity. Analysts have an "Outperform" consensus with an average price target of $40, despite a bearish options flow and recent net selling by insiders. The short interest is declining, which is typically seen as bullish.
Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Dyne Therapeutics reported its Q2 2026 financial results and significant business advancements, including the FDA's acceptance of a Biologics License Application for z-rostudirsen in DMD with Priority Review. The company also completed enrollment for a registrational trial of z-basivarsen in DM1 and received IND clearance for DYNE-302 in FSHD. Dyne projects its cash reserves will fund operations into Q2 2028, following a recent public offering and term loan expansion.
Dyne Therapeutics (NASDAQ: DYN) details $299M loss, advances DMD and DM1 drugs
Dyne Therapeutics reported a net loss of $299.4 million for the first six months of 2026, an increase from $226.2 million in the prior year, primarily due to higher R&D and G&A expenses. Despite the losses, the clinical-stage neuromuscular company maintains strong liquidity with $676.1 million in cash, and projects existing funds plus $405.0 million from a recent equity offering to finance operations into Q2 2028. The company is advancing its lead DMD candidate z-rostudirsen, with an FDA priority review granted and PDUFA date of January 21, 2027, and its DM1 candidate z-basivarsen, which completed enrollment for its registrational cohort and aims for a U.S. launch in H1 2028.
DYNE THERAPEUTICS, INC : RBC RAISES TARGET PRICE TO $35 FROM $30
RBC Capital Markets has increased its target price for DYNE Therapeutics, Inc. (DYN.O) from $30 to $35. This adjustment reflects a positive outlook on the company's financial prospects as assessed by the analyst firm.
Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Dyne Therapeutics has released its financial results for the second quarter of 2026, highlighting significant progress in its clinical programs for genetically driven neuromuscular diseases. Key milestones include the FDA's acceptance of a Biologics License Application for z-rostudirsen in DMD with Priority Review, completion of enrollment for the registrational expansion cohort of ACHIEVE for z-basivarsen in DM1, and IND clearance for DYNE-302 in FSHD. The company projects its cash runway will extend into Q2 2028, following a recent public offering and term loan amendment.
Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Dyne Therapeutics (Nasdaq: DYN) announced its financial results for the second quarter of 2026 and provided key business updates. The company achieved several significant milestones, including the FDA's acceptance of its Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD with Priority Review, and the completion of enrollment for the registrational expansion cohort of the ACHIEVE trial for z-basivarsen in DM1. Dyne also received FDA clearance for its IND application for DYNE-302 in FSHD and projects its cash runway into Q2 2028.
Dyne raises $431M as FDA reviews Duchenne muscular dystrophy drug
Dyne Therapeutics announced significant clinical, regulatory, and financial milestones, raising $431 million through an equity offering and expanding its Hercules term loan facility. The FDA accepted its BLA for z-rostudirsen in exon 51 DMD with Priority Review, setting a PDUFA date of January 21, 2027, and cleared an IND for DYNE-302 in FSHD. The company also completed enrollment for its ACHIEVE trial in DM1, with topline data expected in Q1 2027, and projects its cash reserves to fund operations into Q2 2028 despite increased R&D and G&A expenses.
Dyne Therapeutics (DYN) director-affiliated fund sells 261K shares
Dyne Therapeutics director Dirk Kersten, through ForDyne B.V., reported indirect open-market sales of 261,460 shares of common stock on July 27, 2026, executed under a Rule 10b5-1 trading plan. The sales occurred at weighted average prices of $25.5024 and $26.0428 per share. Kersten disclaims beneficial ownership of the shares except for his pecuniary interest, as the shares are held by ForDyne, which is jointly owned by Forbion funds.
BlackRock (DYN holder) discloses 11.49M Dyne Therapeutics shares, a 7% stake
BlackRock, Inc. has disclosed a 7.0% beneficial ownership stake in Dyne Therapeutics, Inc., holding 11,489,504 shares as of June 30, 2026. The firm maintains sole voting power over 11,273,443 shares and sole dispositive power over all 11,489,504 shares. This filing is a SCHEDULE 13G/A, indicating a passive investment without intent to influence company control, and no single BlackRock client holds more than five percent of Dyne's outstanding common shares.
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy
Dyne Therapeutics has announced U.S. FDA clearance for its Investigational New Drug (IND) application for DYNE-302, a therapy aimed at treating facioscapulohumeral muscular dystrophy (FSHD). This marks the company's third program leveraging its FORCE platform to enter clinical development. DYNE-302 is designed to suppress DUX4 expression, which is implicated in FSHD, and has shown promising preclinical results, including reversal of muscle fiber damage and functional improvement.
Dyne Therapeutics receives FDA clearance for FSHD trial
Dyne Therapeutics has announced that the FDA has cleared its investigational new drug application for DYNE-302, allowing the company to begin a Phase 1 clinical trial for facioscapulohumeral muscular dystrophy (FSHD). This marks Dyne’s third clinical program utilizing its FORCE platform. FSHD is a rare, progressive, inherited muscle disease with no approved therapies, affecting an estimated 15,000 to 40,000 individuals in the United States.
Dyne Targets FSHD, a Muscle Disease With No Approved Therapies
Dyne Therapeutics has received FDA clearance for its Investigational New Drug (IND) application for DYNE-302, allowing it to proceed with a Phase 1 clinical trial for facioscapulohumeral muscular dystrophy (FSHD). DYNE-302, leveraging Dyne's FORCE platform, aims to suppress DUX4 expression which drives FSHD. Preclinical studies showed promising results, including the reversal of muscle fiber damage and functional improvement, positioning it as a potential therapy for this rare genetic muscle disease with no approved treatments.
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)
Dyne Therapeutics has received U.S. FDA clearance for its Investigational New Drug (IND) application for DYNE-302, a therapy aimed at treating facioscapulohumeral muscular dystrophy (FSHD). DYNE-302, which leverages Dyne's FORCE™ platform, is designed to suppress DUX4 expression, the genetic driver of FSHD, and preclinical studies showed promising results in reversing muscle damage. The company plans to initiate a Phase 1 randomized, placebo-controlled clinical trial to evaluate the drug's safety, tolerability, pharmacokinetics, and pharmacodynamics in adult FSHD patients.
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)
Dyne Therapeutics has received U.S. FDA clearance for its IND application to begin a Phase 1 clinical trial for DYNE-302, a potential treatment for facioscapulohumeral muscular dystrophy (FSHD). DYNE-302, developed using Dyne's FORCE platform, aims to suppress DUX4 expression, which is a key driver of the disease. Preclinical studies showed promising results in reversing muscle damage and improving function in FSHD models.
